Company Encyclopedia
View More
name
FOSUN PHARMA
600196.SH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetology respiratory health and professional medical products; oncology, neuroscience and other specialty fields; and solutions for infections, tumors, the central nervous system, and chronic diseases.
3.157 T
600196.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking76/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.89%C
    • Profit Margin8.30%B
    • Gross Margin48.56%B
  • Growth ScoreC
    • Revenue YoY-4.96%D
    • Net Profit YoY55.36%B
    • Total Assets YoY2.48%C
    • Net Assets YoY2.73%C
  • Cash ScoreC
    • Cash Flow Margin1204.82%B
    • OCF YoY-4.96%D
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreC
    • Gearing Ratio48.52%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fosun Pharma Gets Greenlight for Tumor Drug Trials

    Fosun Pharma Gets Greenlight for Tumor Drug Trials

    marketscreener·
    SH
    600196
    +0.63%
    HK
    02196
    +0.47%
    marketscreener·
    SH
    600196
    +0.63%
    HK
    02196
    +0.47%

    Fosun Pharma Subsidiary Wins Approval for Clinical Trial of FXS0887 Tablets

    Shanghai Fosun Pharmaceutical's subsidiary has received approval to conduct a clinical trial for FXS0887 tablets, aimed at treating advanced malignant solid tumors. This development marks a significant step in the company's research and development efforts.

    Reuters·
    SH
    600196
    +0.63%
    HK
    02196
    +0.47%
    Reuters·
    SH
    600196
    +0.63%
    HK
    02196
    +0.47%

    Fosun Pharma Subsidiary Wins Acceptance for Drug Registration Application

    Shanghai Fosun Pharmaceutical announced that its subsidiary's drug registration application has been accepted. This information was published via the Issuer Information Service of the Hong Kong Stock Exchange.

    Reuters·
    SH
    600196
    +0.63%
    HK
    02196
    +0.47%
    Reuters·
    SH
    600196
    +0.63%
    HK
    02196
    +0.47%

    Shanghai Fosun Pharmaceutical Co., Ltd. Announces Pricing Basis and Policy for the Fosun Pharma Services

    Shanghai Fosun Pharmaceutical Co., Ltd. announced the pricing basis and policy for Fosun Pharma Services. Prices will be determined through arm's-length negotiations based on service content, market prices, and terms offered to third parties. The agreement covers medical services, examination services, diagnosis testing, and consulting services, with fees set according to industry standards and market conditions.

    marketscreener·
    HK
    02196
    +0.47%
    SH
    600196
    +0.63%
    marketscreener·
    HK
    02196
    +0.47%
    SH
    600196
    +0.63%

    Fosun International Affiliate Fosun Pharma Expands Mutual Supply Agreement with CQ Pharma Holdings

    Fosun Pharma, an affiliate of Fosun International, has expanded its mutual supply agreement with CQ Pharma Holdings. This extension of the framework agreement signifies a continued collaboration between the two entities. The original content was published by Fosun International via the Hong Kong Stock Exchange's Issuer Information Service on November 28, 2025. The news brief was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    HK
    02196
    +0.47%
    SH
    600196
    +0.63%
    Reuters·
    HK
    02196
    +0.47%
    SH
    600196
    +0.63%
    © 2025 Longbridge｜Disclaimer